Annual Operating Expenses
$407.89 M
-$30.00 K-0.01%
December 31, 2022
Summary
- As of February 24, 2025, SRNE annual total operating expenses is $407.89 million, with the most recent change of -$30.00 thousand (-0.01%) on December 31, 2022.
- During the last 3 years, SRNE annual operating expenses has risen by +$193.51 million (+90.27%).
- SRNE annual operating expenses is now -0.01% below its all-time high of $407.92 million, reached on December 31, 2021.
Performance
SRNE Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$83.34 M
-$16.57 M-16.59%
June 30, 2023
Summary
- As of February 24, 2025, SRNE quarterly total operating expenses is $83.34 million, with the most recent change of -$16.57 million (-16.59%) on June 30, 2023.
- Over the past year, SRNE quarterly operating expenses has dropped by -$16.57 million (-16.59%).
- SRNE quarterly operating expenses is now -30.13% below its all-time high of $119.28 million, reached on September 30, 2022.
Performance
SRNE Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
SRNE Operating Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -0.0% | -16.6% |
3 y3 years | +90.3% | -16.6% |
5 y5 years | +322.8% | -16.6% |
SRNE Operating Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -0.0% | at low | -30.1% | +2.1% |
5 y | 5-year | -0.0% | +90.3% | -30.1% | +72.0% |
alltime | all time | -0.0% | >+9999.0% | -30.1% | >+9999.0% |
Sorrento Therapeutics Operating Expenses History
Date | Annual | Quarterly |
---|---|---|
Jun 2023 | - | $83.34 M(-16.6%) |
Mar 2023 | - | $99.91 M(+22.4%) |
Dec 2022 | $407.89 M(-0.0%) | $81.64 M(-31.6%) |
Sep 2022 | - | $119.28 M(+22.2%) |
Jun 2022 | - | $97.64 M(-10.7%) |
Mar 2022 | - | $109.34 M(-4.8%) |
Dec 2021 | $407.92 M(+76.2%) | $114.85 M(+16.1%) |
Sep 2021 | - | $98.94 M(-6.5%) |
Jun 2021 | - | $105.87 M(+19.9%) |
Mar 2021 | - | $88.26 M(+15.8%) |
Dec 2020 | $231.57 M(+8.0%) | $76.22 M(+33.0%) |
Sep 2020 | - | $57.30 M(+15.5%) |
Jun 2020 | - | $49.60 M(+2.4%) |
Mar 2020 | - | $48.45 M(-12.4%) |
Dec 2019 | $214.38 M(+49.3%) | $55.28 M(+2.7%) |
Sep 2019 | - | $53.84 M(+0.5%) |
Jun 2019 | - | $53.56 M(+3.6%) |
Mar 2019 | - | $51.70 M(+6.8%) |
Dec 2018 | $143.61 M(+48.9%) | $48.41 M(+20.1%) |
Sep 2018 | - | $40.32 M(+36.1%) |
Jun 2018 | - | $29.62 M(+17.3%) |
Mar 2018 | - | $25.25 M(+22.2%) |
Dec 2017 | $96.47 M(+43.5%) | $20.66 M(-24.8%) |
Sep 2017 | - | $27.47 M(+31.2%) |
Jun 2017 | - | $20.94 M(-23.6%) |
Mar 2017 | - | $27.40 M(+14.1%) |
Dec 2016 | $67.24 M(+27.8%) | $24.02 M(+52.4%) |
Sep 2016 | - | $15.76 M(+4.6%) |
Jun 2016 | - | $15.07 M(+21.7%) |
Mar 2016 | - | $12.38 M(-33.2%) |
Dec 2015 | $52.63 M | $18.53 M(+53.6%) |
Sep 2015 | - | $12.07 M(+5.9%) |
Jun 2015 | - | $11.39 M(+7.0%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2015 | - | $10.64 M(+5.4%) |
Dec 2014 | $36.31 M(+125.0%) | $10.10 M(+28.2%) |
Sep 2014 | - | $7.88 M(-4.6%) |
Jun 2014 | - | $8.26 M(-18.1%) |
Mar 2014 | - | $10.08 M(+56.2%) |
Dec 2013 | $16.14 M(+196.9%) | $6.45 M(+90.3%) |
Sep 2013 | - | $3.39 M(-7.1%) |
Jun 2013 | - | $3.65 M(+37.8%) |
Mar 2013 | - | $2.65 M(+41.0%) |
Dec 2012 | $5.44 M(+44.1%) | $1.88 M(+36.3%) |
Sep 2012 | - | $1.38 M(+18.6%) |
Jun 2012 | - | $1.16 M(+14.2%) |
Mar 2012 | - | $1.02 M(+14.2%) |
Dec 2011 | $3.77 M(+51.2%) | $891.20 K(+12.0%) |
Sep 2011 | - | $795.40 K(-31.6%) |
Jun 2011 | - | $1.16 M(+26.3%) |
Mar 2011 | - | $921.40 K(+31.5%) |
Dec 2010 | $2.49 M(+161.5%) | $700.50 K(+25.1%) |
Sep 2010 | - | $559.90 K(-11.5%) |
Jun 2010 | - | $633.00 K(+5.3%) |
Mar 2010 | - | $601.40 K(-12.8%) |
Dec 2009 | $954.10 K(+3612.5%) | $689.90 K(+189.0%) |
Sep 2009 | - | $238.70 K(+832.4%) |
Jun 2009 | - | $25.60 K(-121.6%) |
Dec 2008 | $25.70 K(-89.3%) | -$118.70 K(-194.4%) |
Sep 2008 | - | $125.80 K(+2229.6%) |
Jun 2008 | - | $5400.00(-59.1%) |
Mar 2008 | - | $13.20 K(+78.4%) |
Dec 2007 | $240.60 K(-45.2%) | $7400.00(-30.2%) |
Sep 2007 | - | $10.60 K(-15.9%) |
Jun 2007 | - | $12.60 K(-94.0%) |
Mar 2007 | - | $209.90 K |
Dec 2006 | $439.30 K(-242.6%) | - |
Dec 2005 | -$308.00 K | - |
FAQ
- What is Sorrento Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual operating expenses year-on-year change?
- What is Sorrento Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly operating expenses year-on-year change?
What is Sorrento Therapeutics annual total operating expenses?
The current annual operating expenses of SRNE is $407.89 M
What is the all time high annual operating expenses for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual total operating expenses is $407.92 M
What is Sorrento Therapeutics annual operating expenses year-on-year change?
Over the past year, SRNE annual total operating expenses has changed by -$30.00 K (-0.01%)
What is Sorrento Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of SRNE is $83.34 M
What is the all time high quarterly operating expenses for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly total operating expenses is $119.28 M
What is Sorrento Therapeutics quarterly operating expenses year-on-year change?
Over the past year, SRNE quarterly total operating expenses has changed by -$16.57 M (-16.59%)